ISSN: 1859 - 2872
Botulinum toxin A điều trị đau thần kinh
Main Article Content
Keywords
Độc tố botulinum A (BoNT-A), đau do thần kinh, điều trị đau do thần kinh
Tóm tắt
Botulinum toxin A (BoNT-A) sau gần 3 đến 4 thập kỷ lãng quên vì được xem là độc tố chết người. Đến năm 1980, một bác sĩ nhãn khoa, Alan B Scott người đầu tiên đã sử dụng độc tố trị lé (lác) mắt cho bệnh nhân [1, 2, 3, 4, 5]. Gần 10 năm sau, tháng 12/1989, Cơ quan Thuốc và Dược phẩm Hoa Kỳ (FDA) phê chuẩn onabotulinumtoxin A (Botox®) điều trị, lác (strabismus), co thắt mí mắt (blepharospasm), co thắt nửa mặt (hemifacial spasm) ở trẻ dưới 12 tuổi. Năm 2000, điều trị rối loạn co thắt không tự ý cơ cổ (cervical dystonia) [6, 7, 8, 9]. Một thời gian dài tác dụng giảm đau của BoNT-A được xem là do giãn cơ [1, 10, 11]. Tuy nhiên, gần đây các nghiên cứu cơ chế đau thần kinh nhận thấy tác dụng giảm đau BoNT-A hoàn toàn độc lập với giãn cơ [11, 12, 13, 14, 15, 16]. Trong bài này, chúng tôi xin tóm lược các y văn khảo sát cơ chế tác dụng của BoNT-A trên các cơn đau khó trị do thần kinh như: Đau thần kinh sau nhiễm vi rút Herpes, đau thần kinh do đái tháo đường, hội chứng đau phức hợp vùng (complex regional pain syndrome), đau dây thần kinh tam thoa, đau tận cùng mỏm cụt thần kinh như đau chi ma (phantom limb pain), đau sau thương tổn tủy sống, và đau sau đột quỵ
Article Details
Các tài liệu tham khảo
1. Anthony W, Howard S (2013) Botulinum toxins: Mechanisms of action, antinociception and clinical applications. Toxicology 306: 124-146.
2. Arnon S, Schechter R et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8): 1059-1070 (doi:10.1001/jama.285.8.1059).
3. Erbguth FJ (2007) From poison to remedy: The chequered history of botulinum toxin. J Neural Transm: 1-7.
4. Kate Coleman (2020) Historical Background, botulinum toxin: mode of action and serotypes, clinical indications and use. ln: Kate Coleman (eds). Botrulinum Toxin in Facial Rejuvenation 2: 1-14. Elsevier, Philadelphia PA: 19103-2899.
5. Siddharth A, Carol P, Joyce C et al (2019) Botulinum toxin in strabismus. Strabismus: 147-157. Springer Nature Singapore Pte Ltd. https://doi.org/10.1007/978-981-13-1126-0.
6. Anthony B, Michael P, Khalid A (2007) Introduction to botulinum toxin in clinical practice, Cervical dystonia. Clinical Uses of Botulinum Toxins: 58-102. Cambridge University Press, New York.
7. França K, Kumar A et al (2016) The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr: 1-3. doi. 10.1007/s10354-017-0553-7.
8. Foster KA (2014) Overview and history of botulinum neurotoxin research. ln: Overview and History of Botulinum Neurotoxin Research. Molecular Aspects of Botulinum Neurotoxin, Springer New York 4: 1-8.
9. Mense S (2004) Neurobiological basis for the use of botulinum toxin in pain therapy. J. Neurol 251: 1-7.
10. Jabbari B, Rossetto O (2018) Botulinum toxins: molecular structures and synaptic physiology. Botulinum Toxin Treatment in Clinical Medicine, Springer International Publishing AG: 1-9.
11. Freund B, Schwartz M (2003) Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J. Pain 4: 159-165.
12. Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43: 9-15.
13. Argoff CE (2003) The use of botulinum toxins for chronic pain and headaches. Curr.Treat. Options Neurol 5: 483-492.
14. Bohluli B, Motamedi M et al (2011) Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg. Oral Med. Oral Pathol, Endod 111: 47-50.
15. Francisco G, Tan H, Green M (2012) Do botulinum toxins have a role inthe management of neuropathic pain? A focused review. Am. J. Phys.Med. Rehabil 91: 899-909.
16. Tsui J, Eisen A et al (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2: 245-247.
17. Stell R, Thompson P, Marsden C (1988) Botulinum toxin in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry 51: 920-923.
18. Relja M, Klepac N (2002) Different doses of botulinum toxin A and pain responsiveness in cervical dystonia.Neurology 58: 474.
19. Kyle KS (2017) Botoxology. Botulinum Toxin for Asians (eds), Springer Science+Business Media Singapore: 1-27.
20. Verderio C, Grumelli C et al (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8: 142-153.
21. Cui M, Khanijou S, Rubino J, Aoki K (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107: 125-133.
22. Lee W, Shin T et al (2011) Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced antinociceptive responses in mice. Anesth. Analg 112: 228-235.
23. Matak I, Bölcskei K et al (2019) Mechanisms of botulinum toxin type A action on pain. Toxins 11: 459: 1-26 doi: 10.3390/toxins11080459.
24. Oh H, Chung M (2015) Botulinum toxin for neuropathic pain: A review of the literature toxins 7: 3127-3154. doi:10.3390/toxins7083127.
25. Welch M, Purkiss J, Foster K (2000) Sensitivity of embryonic rat dorsal root ganglia Neurons to Clostridium botulinum neurotoxins. Toxicon 38: 245–258.
26. Durham P, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 44: 35-42.
27. Aoki KR (2005) Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A. Neurotoxicology 26: 785-793.
28. Park J, Chung M (2018) Botulinum toxin for central neuropathic pain toxins. Toxins (Basel). 10(6):224.10(224): 1-14 doi:10.3390/toxins10060224.
29. Cheng J, Liu W, Duffney L, Yan Z (2013) SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors. J. Physiol 591: 3935-3947.
30. Morenilla-Palao C, Planells-Cases R et al (2004) Regulated exocytosis contributes to protein kinase c potentiation of vanilloid receptor activity. The Journal of Biological Chemistry 279(24): 25665-25672.
31. Erbguth FJ (2004) Historical notes on botulism, clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Movement Disorders 19(8): 2-9 .
32. Jankovic J (2017) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 147:84-88. doi: 10.1016/j.toxicon. 2017. 09.003.
33. Jeynes L, Gauci C (2008) Evidence for the use of botulinum toxin in the chronic pain setting: A review of the literature. Pain Pract 8: 269-276.
34. Kharkar S, Ambady P, Venkatesh Y, Schwartzman R (2014) Intramuscular botulinum toxin in complex regional pain syndrome: Case series and literature review. Pain Phys14: 419-424.
35. Meng J Ovsepian et al, Activation of TRPV1 mediates calcitonin gene-related peptide release,which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci 29: 4981-4992.
36. Safarpour Y, Jabbari B (2018) Botulinum toxin treatment of pain syndromes an evidence based review. Toxicon: 1-35.
37. Yuan R, Sheu J et al (2009) Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 72: 1473-1478.
38. Ghasemi M, Ansari M, Basiri K, Shaigannejad V, The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy. J. Res. Med. Sci 19: 106-111.
39. Nam KE, Kim JS et al (2017) Botulinum toxin type a injection for neuropathic pain in a patient with a brain tumor: A case report. Ann Rehabil Med 41(6): 1088-1092.
40. Grumelli C, Corradini I, Matteoli M, Verderio C (2010) Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium 47: 419-424.
41. Layeeque R,Hochberg R et al (2004) Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg 240: 608-614.
42. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D (2010) Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med 11: 1827-1833.
43. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D (2013) Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo- controlled trial. Clin. J. Pain 29: 857-864.
44. Ranoux D, Attal N, Morain F, Bouhassira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64: 274-283.
45. Wu J, Lian J et al (2012) Botulinum toxin type A for the treatment of trigeminal neuralgias: Results from a randomized, double-blind, placebo-controlled trial. Cephalgia 32: 443-450.
46. Zhang H, Lian Y et al (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double- blind, placebo-controlled trial. The Journal of Headache and Pain 15(65): 1-6.
47. Piovesan E, Teive G, Kowacs A, Della Coletta M, Werneck L, Silberstein D (2005) An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 65: 1306-1308.
48. Carroll I, Clark D, Mackey S (2009) Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann. Neurol. 65: 348-351.
49. Wu H, Sultana R, Taylor KB, Szabo A (2012) A prospective randomized double- blinded pilot study to examine the effect of botulinum toxin type A injection versus Lidocaine/Depomedrol injection on residual and phantom limb pain: Initial report. Clin. J. Pain 28: 108-112.
50. Han A, Song H, Oh H, Chung M (2016) Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol 79: 569-578.
51. Shaw C, Price I, van Wijck M, Shackley P, Steen N, Barnes M, Ford G, Graham L, Rodgers H, Bo T (2011) Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: Effect on impairment, activity limitation, and pain. Stroke 42: 1371-1379.
52. Lim J, Koh J, Paik N (2008) Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 39: 126-131.
53. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, Escalada F, Espadaler J (2007) Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J. Rehabil. Med 39: 440-447.
54. Yelnik A, Colle F, Bonan I, Vicaut E (2007) Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: A randomised, double blind, placebo controlled study of botulinum toxin A. J. Neurol. Neurosurg. Psychiatry 78: 845-848.
55. Schuler A, Veenstra J et al (2019) Battling Neuropathic Scar Pain with Botulinum Toxin. Jounal of Drug Dermatology 18(9): 937-938.
56. Jensen T (2011) A new definition of neuropathic pain. Commentary/PAIN 152: 2204-2205.
2. Arnon S, Schechter R et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8): 1059-1070 (doi:10.1001/jama.285.8.1059).
3. Erbguth FJ (2007) From poison to remedy: The chequered history of botulinum toxin. J Neural Transm: 1-7.
4. Kate Coleman (2020) Historical Background, botulinum toxin: mode of action and serotypes, clinical indications and use. ln: Kate Coleman (eds). Botrulinum Toxin in Facial Rejuvenation 2: 1-14. Elsevier, Philadelphia PA: 19103-2899.
5. Siddharth A, Carol P, Joyce C et al (2019) Botulinum toxin in strabismus. Strabismus: 147-157. Springer Nature Singapore Pte Ltd. https://doi.org/10.1007/978-981-13-1126-0.
6. Anthony B, Michael P, Khalid A (2007) Introduction to botulinum toxin in clinical practice, Cervical dystonia. Clinical Uses of Botulinum Toxins: 58-102. Cambridge University Press, New York.
7. França K, Kumar A et al (2016) The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr: 1-3. doi. 10.1007/s10354-017-0553-7.
8. Foster KA (2014) Overview and history of botulinum neurotoxin research. ln: Overview and History of Botulinum Neurotoxin Research. Molecular Aspects of Botulinum Neurotoxin, Springer New York 4: 1-8.
9. Mense S (2004) Neurobiological basis for the use of botulinum toxin in pain therapy. J. Neurol 251: 1-7.
10. Jabbari B, Rossetto O (2018) Botulinum toxins: molecular structures and synaptic physiology. Botulinum Toxin Treatment in Clinical Medicine, Springer International Publishing AG: 1-9.
11. Freund B, Schwartz M (2003) Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J. Pain 4: 159-165.
12. Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43: 9-15.
13. Argoff CE (2003) The use of botulinum toxins for chronic pain and headaches. Curr.Treat. Options Neurol 5: 483-492.
14. Bohluli B, Motamedi M et al (2011) Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg. Oral Med. Oral Pathol, Endod 111: 47-50.
15. Francisco G, Tan H, Green M (2012) Do botulinum toxins have a role inthe management of neuropathic pain? A focused review. Am. J. Phys.Med. Rehabil 91: 899-909.
16. Tsui J, Eisen A et al (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2: 245-247.
17. Stell R, Thompson P, Marsden C (1988) Botulinum toxin in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry 51: 920-923.
18. Relja M, Klepac N (2002) Different doses of botulinum toxin A and pain responsiveness in cervical dystonia.Neurology 58: 474.
19. Kyle KS (2017) Botoxology. Botulinum Toxin for Asians (eds), Springer Science+Business Media Singapore: 1-27.
20. Verderio C, Grumelli C et al (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8: 142-153.
21. Cui M, Khanijou S, Rubino J, Aoki K (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107: 125-133.
22. Lee W, Shin T et al (2011) Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced antinociceptive responses in mice. Anesth. Analg 112: 228-235.
23. Matak I, Bölcskei K et al (2019) Mechanisms of botulinum toxin type A action on pain. Toxins 11: 459: 1-26 doi: 10.3390/toxins11080459.
24. Oh H, Chung M (2015) Botulinum toxin for neuropathic pain: A review of the literature toxins 7: 3127-3154. doi:10.3390/toxins7083127.
25. Welch M, Purkiss J, Foster K (2000) Sensitivity of embryonic rat dorsal root ganglia Neurons to Clostridium botulinum neurotoxins. Toxicon 38: 245–258.
26. Durham P, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 44: 35-42.
27. Aoki KR (2005) Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A. Neurotoxicology 26: 785-793.
28. Park J, Chung M (2018) Botulinum toxin for central neuropathic pain toxins. Toxins (Basel). 10(6):224.10(224): 1-14 doi:10.3390/toxins10060224.
29. Cheng J, Liu W, Duffney L, Yan Z (2013) SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors. J. Physiol 591: 3935-3947.
30. Morenilla-Palao C, Planells-Cases R et al (2004) Regulated exocytosis contributes to protein kinase c potentiation of vanilloid receptor activity. The Journal of Biological Chemistry 279(24): 25665-25672.
31. Erbguth FJ (2004) Historical notes on botulism, clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Movement Disorders 19(8): 2-9 .
32. Jankovic J (2017) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 147:84-88. doi: 10.1016/j.toxicon. 2017. 09.003.
33. Jeynes L, Gauci C (2008) Evidence for the use of botulinum toxin in the chronic pain setting: A review of the literature. Pain Pract 8: 269-276.
34. Kharkar S, Ambady P, Venkatesh Y, Schwartzman R (2014) Intramuscular botulinum toxin in complex regional pain syndrome: Case series and literature review. Pain Phys14: 419-424.
35. Meng J Ovsepian et al, Activation of TRPV1 mediates calcitonin gene-related peptide release,which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci 29: 4981-4992.
36. Safarpour Y, Jabbari B (2018) Botulinum toxin treatment of pain syndromes an evidence based review. Toxicon: 1-35.
37. Yuan R, Sheu J et al (2009) Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 72: 1473-1478.
38. Ghasemi M, Ansari M, Basiri K, Shaigannejad V, The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy. J. Res. Med. Sci 19: 106-111.
39. Nam KE, Kim JS et al (2017) Botulinum toxin type a injection for neuropathic pain in a patient with a brain tumor: A case report. Ann Rehabil Med 41(6): 1088-1092.
40. Grumelli C, Corradini I, Matteoli M, Verderio C (2010) Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium 47: 419-424.
41. Layeeque R,Hochberg R et al (2004) Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg 240: 608-614.
42. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D (2010) Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med 11: 1827-1833.
43. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D (2013) Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo- controlled trial. Clin. J. Pain 29: 857-864.
44. Ranoux D, Attal N, Morain F, Bouhassira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64: 274-283.
45. Wu J, Lian J et al (2012) Botulinum toxin type A for the treatment of trigeminal neuralgias: Results from a randomized, double-blind, placebo-controlled trial. Cephalgia 32: 443-450.
46. Zhang H, Lian Y et al (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double- blind, placebo-controlled trial. The Journal of Headache and Pain 15(65): 1-6.
47. Piovesan E, Teive G, Kowacs A, Della Coletta M, Werneck L, Silberstein D (2005) An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 65: 1306-1308.
48. Carroll I, Clark D, Mackey S (2009) Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann. Neurol. 65: 348-351.
49. Wu H, Sultana R, Taylor KB, Szabo A (2012) A prospective randomized double- blinded pilot study to examine the effect of botulinum toxin type A injection versus Lidocaine/Depomedrol injection on residual and phantom limb pain: Initial report. Clin. J. Pain 28: 108-112.
50. Han A, Song H, Oh H, Chung M (2016) Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol 79: 569-578.
51. Shaw C, Price I, van Wijck M, Shackley P, Steen N, Barnes M, Ford G, Graham L, Rodgers H, Bo T (2011) Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: Effect on impairment, activity limitation, and pain. Stroke 42: 1371-1379.
52. Lim J, Koh J, Paik N (2008) Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 39: 126-131.
53. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, Escalada F, Espadaler J (2007) Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J. Rehabil. Med 39: 440-447.
54. Yelnik A, Colle F, Bonan I, Vicaut E (2007) Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: A randomised, double blind, placebo controlled study of botulinum toxin A. J. Neurol. Neurosurg. Psychiatry 78: 845-848.
55. Schuler A, Veenstra J et al (2019) Battling Neuropathic Scar Pain with Botulinum Toxin. Jounal of Drug Dermatology 18(9): 937-938.
56. Jensen T (2011) A new definition of neuropathic pain. Commentary/PAIN 152: 2204-2205.
Article Sidebar
Đã đăng
Aug 6, 2022
Số tạp chí
Chuyên mục
Articles
Trích dẫn bài viết này
ThảoN. P., & MinhN. H. (2022). Botulinum toxin A điều trị đau thần kinh. Journal of 108 - Clinical Medicine and Phamarcy, 17(6). https://doi.org/10.52389/ydls.v17i6.1380